|
Enhanced Training and Mentorship of Hematologic Oncologists
|
2R25CA168526-06
|
$306,150
|
SUNG, LILLIAN
|
AMERICAN SOCIETY OF HEMATOLOGY
|
|
Human natural killer cells: Advancing biology and clinical applications
|
7R35CA210087-02
|
$992,214
|
CALIGIURI, MICHAEL
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple Myeloma
|
5R01CA212119-02
|
$580,951
|
CHEN, YUAN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Reolysin-based combination therapy in relapsed multiple myeloma
|
5R01CA194742-03
|
$574,645
|
PICHIORRI, FLAVIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
2P30CA033572-35
|
$2,543,187
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S3
|
$865,000
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-35S1
|
$43,750
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S1
|
$3,249,644
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S2
|
$1,000,000
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-05
|
$8,073,787
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Transient anti-BCMA CAR T-cells for Treatment of Multiple Myeloma
|
1R43CA221432-01A1
|
$299,042
|
STEWART, CHARLES
|
CARTESIAN THERAPEUTICS, INC.
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-28
|
$5,637,954
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-28S1
|
$249,965
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Contribution of Gynecologic and Breast Cancer Biospecimens from African American women to HCMI
|
3P30CA043703-28S2
|
$48,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-05
|
$1,187,291
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A novel T-cell subset able to kill relapsed cancers
|
5R01CA200539-03
|
$362,569
|
YI, QING
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Targeting macrophages to sensitize myeloma to immune checkpoint blockade
|
5R01CA214811-02
|
$328,888
|
YI, QING
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Validating Rapid Microfluidic Isolation of Personalized Aptamers for Monitoring Minimal Residual Disease in Multiple Myeloma
|
5R33CA196470-03
|
$386,051
|
LIN, QIAO
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
5R01CA193890-04
|
$366,000
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The Role of MMP13 in Multiple Myeloma Bone Disease
|
5R01CA175313-05
|
$331,098
|
LENTZSCH, SUZANNE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S1
|
$120,000
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S2
|
$60,000
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant - PDXNet Supplement
|
3P30CA013696-44S3
|
$126,563
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S4
|
$191,726
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S5
|
$237,191
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S6
|
$246,815
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S7
|
$224,982
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S8
|
$126,563
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S9
|
$250,000
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-44
|
$3,972,720
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
|
5R01CA050947-26
|
$301,545
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma
|
5R01CA207237-03
|
$395,166
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer
|
5R50CA211399-03
|
$264,110
|
BIRD, GREGORY
|
DANA-FARBER CANCER INST
|
|
USP7 inhibitors for the treatment of multiple myeloma
|
5R01CA211681-02
|
$504,721
|
BUHRLAGE, SARA
|
DANA-FARBER CANCER INST
|
|
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
|
5U10CA180867-05
|
$1,302,199
|
BURSTEIN, HAROLD
|
DANA-FARBER CANCER INST
|
|
Validating the eCyPA/CD147 signaling complex for myeloma therapy
|
5R01CA196783-04
|
$394,823
|
CARRASCO, RUBEN
|
DANA-FARBER CANCER INST
|
|
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.
|
5R01CA214608-02
|
$410,426
|
FISCHER, ERIC
|
DANA-FARBER CANCER INST
|
|
Stroma-mediated clonal evolution in Multiple Myeloma
|
5R01CA181683-05
|
$353,770
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)
|
5R01CA205954-03
|
$703,249
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S1
|
$445,796
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S2
|
$59,495
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S3
|
$62,500
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S4
|
$149,528
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S5
|
$60,691
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S6
|
$228,108
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S7
|
$199,806
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
5P30CA006516-53
|
$11,504,298
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
ECOG-ACRIN Network Group Statistics and Data Management Center
|
5U10CA180794-05
|
$7,856,253
|
GRAY, ROBERT
|
DANA-FARBER CANCER INST
|
|
Functional and biologic significance of deacetylase3 inhibition in myeloma
|
5R01CA178264-05
|
$353,291
|
HIDESHIMA, TERU
|
DANA-FARBER CANCER INST
|
|
Determining the mutational landscape of circulating multiple myeloma cells
|
5K08CA191026-04
|
$177,120
|
LOHR, JENS
|
DANA-FARBER CANCER INST
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|